Verrica Pharmaceuticals "announced the pricing of its underwritten offering of 750,000 shares of its common stock and pre-funded warrants to purchase 4,064,814 shares of common stock. The shares of common stock are being sold at a price of $6.75 per share and the pre-funded warrants are being sold at a price of $6.7499 per share. The offering is being substantially led by one healthcare dedicated fund. The gross proceeds from the offering to Verrica are expected to be approximately $32.5 million, before deducting underwriting discounts and commissions and offering expenses. The offering is expected to close on or about February 23, 2023, subject to customary closing conditions. Jefferies LLC is acting as sole book-runner for the offering."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VRCA:
- Verrica Announces Pricing of $32.5 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
- RBC upgrades Verrica Pharmaceuticals to Outperform on improved VP-102 view
- Verrica upgraded to Outperform from Sector Perform at RBC Capital
- Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
- Verrica Pharmaceuticals resubmits NDA for VP-102 in molluscum contagiosum